Track Immatics N.V. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Immatics N.V. IMTX · Stock Open Immatics N.V. in new tab

6.39 USD
EPS
-1.92
P/B
1.97
ROE
-54.26
Beta
1.35
Target Price
16.40 USD
Loading chart...
Key Metrics
Earnings dateNov. 17, 2026
EPS-1.92
Book Value3.24
Price to Book1.97
Debt/Equity3.18
% Insiders15.945%
Growth
Revenue Growth0.34%
Estimates
Forward P/E-3.15
Forward EPS-2.03
Target Mean Price16.40

DCF valuation

Model fair value for Immatics N.V. (IMTX)
Result
Sign in to run the valuation for IMTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Strong buy · mean target 16.40 USD (low 11.80, high 21.00) · as of 14 Nov 2026
Low 11.80
Mean 16.40
High 21.00
Price 6.39
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Immatics N.V. Logo Immatics N.V. Analysis (IMTX)

Germany Health Care Official Website Stock

Is Immatics N.V. a good investment? Immatics N.V. (IMTX) is currently trading at 6.39 USD. Market analysts have a consensus price target of 16.40 USD. This suggests a potential upside from current levels.

Earnings Schedule: Immatics N.V. is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -2.03.

Investor FAQ

Does Immatics N.V. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Immatics N.V.?

Immatics N.V. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -1.92.

Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Exchange Ticker
NMS (United States) IMTX
BER (Germany) 4A3.BE
DUS (Germany) 4A3.DU
MUN (Germany) 4A3.MU
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion